May 2026 - New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia

NIKTIMVO was assessed through the TGA’s Priority Review pathway and is the first approved anti-colony stimulating factor-1 receptor (anti-CSF-1R) antibody for cGVHD.